Embecta Corp.'s stock plunged 5.99% on Thursday's trading session, following the release of its fiscal Q1 2025 earnings report.
The medical device company reported adjusted earnings of $0.65 per share for the quarter ended December 31, exceeding analysts' expectations of $0.44. However, Embecta lowered its full-year 2025 revenue guidance to $1.08 billion to $1.09 billion, down from the previous range of $1.09 billion to $1.11 billion. This reduced outlook weighed on investor sentiment, leading to the stock's decline.
Despite the revenue guidance cut, Embecta maintained its adjusted earnings per share forecast for fiscal 2025 at $2.70 to $2.90, in line with analysts' estimates of $2.80. The company also reported a dividend of $0.15 for the quarter.
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。